Similar articles

• [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].

  de Bruin-Weller MS, Bruijnzeel-Koomen CA. de Bruin-Weller MS, et al. Ned Tijdschr Geneeskd. 2005 May 14;149(20):1096-100. Ned Tijdschr Geneeskd. 2005. PMID: 15932135 Review. Dutch.
• [Topical calcineurin inhibitors in atopic eczema -- pro].

  Wollenberg A. Wollenberg A. Dtsch Med Wochenschr. 2006 Jul 14;131(28-29):1614. doi: 10.1055/s-2006-947807. Dtsch Med Wochenschr. 2006. PMID: 16823713 German. No abstract available.
• [Viewpoint of the German Dermatologic Society (DDG) concerning the decision of the American Food and Drug Administration (FDA) on the use of pimecrolimus cream and tacrolimus ointment in the treatment of atopic dermatitis (neurodermatitis)].

  Luger TA, Gollnick H. Luger TA, et al. J Dtsch Dermatol Ges. 2005 Jun;3(6):415-6. doi: 10.1111/j.1610-0387.2005.05038.x. J Dtsch Dermatol Ges. 2005. PMID: 15892843 German. No abstract available.
• [Therapy of atopic eczema with calcineurin inhibitors].

  Luger TA, Bieber T, Meurer M, Mrowietz U, Schwarz T, Simon J, Werfel T, Zuberbier T. Luger TA, et al. J Dtsch Dermatol Ges. 2005 May;3(5):385-91. J Dtsch Dermatol Ges. 2005. PMID: 16372807 German. No abstract available.
• The role of topical calcineurin inhibitors in atopic dermatitis.

  Alomar A, Berth-Jones J, Bos JD, Giannetti A, Reitamo S, Ruzicka T, Stalder JF, Thestrup-Pedersen K; European Working Group on Atopic Dermatitis. Alomar A, et al. Br J Dermatol. 2004 Dec;151 Suppl 70 Dec 2004:3-27. doi: 10.1111/j.1365-2133.2004.06269.x. Br J Dermatol. 2004. PMID: 15548171 Review.